🎗️Thank you to more than 100 people who already helped us by filling out the survey! 🙏 We still need additional voices to help us and brain tumor patients by taking this short survey on liquid biopsies.Just fill it out online here until July 14th👇.

🎗️🧠 Danke an all die hervorragenden Vortragenden der ERSTEN Patient:innentagung für Hirntumore im Kindes- und Jugendalter 👶👧👦 gelebte interdisziplinäre Zusammenarbeit 👩‍⚕️👨‍⚕️@MedUni_Wien #kinderkrebs #cccvienna

🎗️🧠Danke an Gesundheits- und Sozialminister @johannes_rauch für die ergreifende und motivierende Eröffnungsrede zur ersten Patient:innentagung für Hirntumore des Kindes- und Jugendalters @MedUni_Wien Hirntumore sind die häufigste Krebserkrankung bei Kindern, 🙏 für den Support!

The countdown is running for day two of the 3rd Vienna Pediatric Brain Tumor Symposium @MedUni_Wien. We continue with excellent speakers and our first ever patient day. We are honored to welcome @johannes_rauch .Of course we continue with a lot of snow globes to be awarded 🧠🎡

💧Liquid biopsies are an emerging diagnostic tool likely to transform the way we treat children and adolescents suffering from brain tumors. Participate in our survey among patients, families and health care providers and help us shape the future!.👇

We are thrilled to host fantastic speakers at our 3rd Vienna Pediatric Brain Tumor Symposium. Big thank you to @CarlKoschmann, Michal Zapotocky, Philipp Euskirchen, Eelco Hoving for joining our exciting meeting where we are “Translating Science to Patient Benefit” @MedUni_Wien

I am honored that our project was selected!!! Big thank you to everyone making this possible @NBTStweets @CERNfoundation.Within a great team together with @FilbinMariella @LoetschD @WalterBerger19 we seek to find better treatments for high-risk ependymoma #epENDymoma.

RT @NBTStweets: NBTS is excited to announce that Johannes Gojo, MD, PhD, of Medical University of Vienna, is the recipient of the first-eve….

🧠🎗️Finally out - MEMMAT provides survival benefit for a subgroup of patients suffering from recurrent medulloblastoma. Fantastic international collaboration led by @andreaspeyrl @MedUni_Wien. Check it out here 👇.

RT @NTRKers: The @NTRKers virtual Patient Summit, on November 9th, is less than a month away. Check out an exclusive sneak peek of the agen….

🏃‍♂️🏃‍♀️ I am proud of our amazing team of the 🎗️pediatric brain tumor center🧠 @MedUni_Wien and @CCCVienna running today's Cancer Research Run in Vienna! Making a difference for children with brain tumors in the clinics and labs - and on the running track💪

RT @MedUni_Wien: Das @CCCVienna beteiligt sich an der Gründung einer gemeinnützigen GmbH, die maßgeschneiderte Therapien für aggressive For….

RT @CCCVienna: Europaweite präklinische Testplattform für seltene Tumoren bei Kindern etabliert und für die Zukunft gesichert. @MedUni_Wien….

🧬Check out our next work on liquid biopsy in pediatric brain tumors 🧠🎗️@MedUni_Wien.We present a sensitive method to track MYC-amplified medulloblastoma in cerebrospinal fluid👇👇👇.

We are thrilled to share our latest work @MedUni_Wien on liquid biopsies in pediatric brain tumors 🧬🩸miRNAs can be used to track ETMR 👇

Happy to share our latest study on novel therapies against high-risk brain tumors led by JM Penninger @IMBA_Vienna. Fantastic use of our patient-derived tumor models @MedUni_Wien to prove preclinical activity of novel therapeutic approaches! 🔬👇.

RT @FilbinMariella: Introducing the Brain Cancer Revengers! A team of dedicated physician scientist with only one goal: to end pediatric br….

RT @NeuroOnc: Join us for the next broadcast of the Pediatric Tumor Board Series. The broadcast entitled Embryonal tumor with multilayered….

RT @KiTZ_HD: ❗️Last call for abstracts❗️. #ISPNO2022 abstract submission deadline is today 👇.

RT @CD_AACR: Just published! We proudly present "Hallmarks of Cancer: New Dimensions" by Douglas Hanahan, the third update to the seminal s….